Pharmaceutical Autonomy and Public Health in Latin America State, Society and Industry in Brazil’s AIDS Program Routledge Studies in Latin American Politics Series

Brazil has occupied a central role in the access to medicines movement, especially with respect to drugs used to treat those with the human immunodeficiency virus (HIV) that causes the acquired immune deficiency syndrome (AIDS). How and why Brazil succeeded in overcoming powerful political and economic interests, both at home and abroad, to roll-out and sustain treatment represents an intellectual puzzle.

In this book, Matthew Flynn traces the numerous challenges Brazil faced in its efforts to provide essential medicines to all of its citizens. Using dependency theory, state theory, and moral underpinnings of markets, Flynn delves deeper into the salient factors contributing to Brazil?s successes and weaknesses, including control over technology, creation of political alliances, and instrumental use of normative frameworks and effectively explains the ability of countries to fulfill the prescription drug needs of its population versus the interests and operations of the global pharmaceutical industry

Pharmaceutical Autonomy and Public Health in Latin America is one of the only books to provide an in-depth account of the challenges that a developing country, like Brazil, faces to fulfill public health objectives amidst increasing global economic integration and new international trade agreements. Scholars interested in public health issues, HIV/AIDS, and human rights, but also to social scientists interested in Latin America and international political economy will find this an original and thought provoking read.

Selected Contents: Introduction: Access to AIDS Medicines, Public Health, and the Brazilian Solution 1. Pharmaceutical Autonomy: Technology, Alliances and Norms 2. Elements of Global Pharmaceutical Power 3. The Brazilian Context: Contradictions between Democracy and Neoliberalism 4. Asserting Antiretroviral Autonomy (1992-2002) 5. Patent Power and the Limits of Treatment Activism Autonomy (2003-2006) 6. Consolidating the Pharmaceutical Alliance (2007-2013) Conclusion